Best Plasmid DNA CDMOs in China
· updated as new inspection, certificate, and trial data enters the platform
5
CDMOs tracked
2
Fully scored
Plasmid DNA is the upstream starting material for viral vectors, mRNA, and DNA therapeutics — which makes plasmid supply a frequent bottleneck for the entire advanced-therapy pipeline. Plasmid CDMOs run microbial (E. coli) fermentation, alkaline lysis, and chromatographic purification to GMP grade.
Selecting a plasmid CDMO turns on GMP vs research grade, supercoiled fraction and purity, fermentation scale, and lead time. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
Last updated 2026-08-31. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
UB
uBriGene Biosciences
Shanghai, CN · Boston, MA
|
60.5 | — | — | — | 0 programs |
| 2 |
CoJourney Inc.
Horsham, PA (US HQ); Hangzhou, China (primary GMP manufacturing)
|
60.0 | — | — | Limited | 0 programs |
| — |
AsymBio
Shanghai, China
|
Profiled | — | — | — | 0 programs |
| — |
Canton Biologics Co., Ltd.
Foshan (Shunde District), China
|
Profiled | — | — | — | 0 programs |
| — |
Canton Biologics
Guangzhou, China
|
Profiled | — | — | — | 0 programs |
What to evaluate in a Plasmid DNA CDMO
GMP grade & purity
Confirm GMP (vs research/HQ) grade, supercoiled percentage, and residual host-cell DNA/RNA and endotoxin specs — these gate downstream vector and mRNA quality.
Fermentation scale & yield
Match fermentation scale and yield to your vector or mRNA demand. Ask about high-yield strains and whether scale-up is validated.
Lead time
Plasmid is a common critical-path bottleneck. Evaluate realistic queue and turnaround against your program timeline.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
How do the BioSecure Act and 1260H list affect Chinese CDMO selection for US programs?
US sponsors evaluating Chinese CDMOs currently face two active US regulatory considerations. The DoD 1260H list designates named Chinese companies as "Chinese Military Companies" — WuXi AppTec was added in June 2026. Listing itself doesn't restrict commercial pharma work but affects federally-funded research access and creates procurement complications for sponsors with government contracts. The BioSecure Act is proposed federal legislation that would restrict federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies (specifically BGI, MGI, Complete Genomics, WuXi AppTec, and WuXi Biologics as of current drafts). The bill has not passed as of 2026-08 but has bipartisan support. CDMO Signal does not encode US political risk into the Signal Score — the composite reflects regulatory quality, operations, financial stability, and capacity. Sponsors evaluating a Chinese CDMO for US-supplying programs should evaluate US regulatory risk separately as a distinct decision layer.
Chinese CDMOs with FDA and EMA inspection posture
Chinese CDMOs supplying US and European markets need active FDA and EMA GMP certifications on the specific facility. The FDA and EMA both conduct facility inspections in China, and Chinese CDMOs' inspection outcomes have generally improved over the past decade. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly. Chinese CDMOs with cross-jurisdictional certification rank higher on this pillar than domestic-market-only competitors. Cross-check with the US region ranking — Chinese CDMOs appearing on both rankings have demonstrated cross-jurisdictional inspection posture, which materially reduces regulatory risk for programs supplying US markets.
Which modality classes have the strongest Chinese CDMO capability?
China's CDMO capability is strongest in biologics (both mAb and biosimilar), viral vectors (particularly AAV, with substantial commercial-scale capacity via WuXi Advanced Therapies and others), and mRNA (rapid post-COVID capacity build). Small molecule and API manufacturing capacity is also substantial but sits outside CDMO Signal's primary coverage focus. Cross-reference with modality pages to filter Chinese CDMOs by capability: biologics, AAV, mRNA, or the viral vector umbrella. Individual profile pages surface facility-level detail.
Plasmid DNA CDMOs — Frequently Asked Questions
Who are the top Plasmid DNA CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Plasmid DNA CDMOs include uBriGene Biosciences, CoJourney Inc.. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
What should I look for in a plasmid DNA CDMO?
Confirm GMP grade and purity specs (supercoiled %, residual host DNA, endotoxin), fermentation scale and yield for your demand, realistic lead time, and a clean FDA and EMA/MHRA record.
Why is plasmid DNA supply often a bottleneck?
Plasmid is the starting material for viral vectors and mRNA, so a single GMP plasmid lot gates multiple downstream steps. Constrained GMP fermentation capacity and long queues make it a frequent critical-path item.
Related modalities